In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets
Ann Intern Med
.
2020 Apr 21;172(8):JC40.
doi: 10.7326/ACPJ202004210-040.
Authors
Wern Yew Ding
,
Mark Field
,
Gregory Y H Lip
PMID:
32311724
DOI:
10.7326/ACPJ202004210-040
No abstract available
Publication types
Comment
MeSH terms
Anticoagulants
Factor Xa Inhibitors
Humans
Rivaroxaban*
Transcatheter Aortic Valve Replacement*
Substances
Anticoagulants
Factor Xa Inhibitors
Rivaroxaban